Advertisement

Topics

PubMed Journals Articles About "Sopherion Therapeutics" RSS

06:15 EDT 21st October 2017 | BioPortfolio

Sopherion Therapeutics PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Sopherion Therapeutics articles that have been published worldwide.

More Information about "Sopherion Therapeutics" on BioPortfolio

We have published hundreds of Sopherion Therapeutics news stories on BioPortfolio along with dozens of Sopherion Therapeutics Clinical Trials and PubMed Articles about Sopherion Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sopherion Therapeutics Companies in our database. You can also find out about relevant Sopherion Therapeutics Drugs and Medications on this site too.

Showing "Sopherion Therapeutics" PubMed Articles 1–25 of 1,300+

Robert Burton Nussenblatt, MD, MPH (1948-2016), Physician-Scientist, Leading Ophthalmologist and Exemplary Teacher.


Response to Aslankurt et al. re: "Safety Profile of Stromal Hydration of Clear Corneal Incisions with Cefuroxime in the Mouse Model".

Is the Eye an Extension of the Brain in Central Nervous System Disease?


Re: "Safety Profile of Stromal Hydration of Clear Corneal Incisions with Cefuroxime in the Mouse Model" by Moosajee et al. (J. Ocul. Pharmacol. Ther. 32:469-475, 2016).

Special Issue in Honor of Robert B. Nussenblatt, MD, MPH.

Retraction of: Azithromycin 1.5% Ophthalmic Solution for Blepharitis Treatment: Comparison of 14- Versus 30-Day Treatment; DOI: 10.1089/jop.2015.0099.

Eyes on New Product Development.

Eyes on New Product Development.

Eyes on New Product Development.

Eyes on New Product Development.

Eyes on New Product Development.

Overcoming cellular barriers for RNA therapeutics.

RNA-based therapeutics, such as small-interfering (siRNAs), microRNAs (miRNAs), antisense oligonucleotides (ASOs), aptamers, synthetic mRNAs and CRISPR-Cas9, have great potential to target a large part of the currently undruggable genes and gene products and to generate entirely new therapeutic paradigms in disease, ranging from cancer to pandemic influenza to Alzheimer's disease. However, for these RNA modalities to reach their full potential, they first need to overcome a billion years of evolutionary def...

The Potential for Emerging Microbiome-Mediated Therapeutics in Asthma.

In terms of immune regulating functions, analysis of the microbiome has led the development of therapeutic strategies that may be applicable to asthma management. This review summarizes the current literature on the gut and lung microbiota in asthma pathogenesis with a focus on the roles of innate molecules and new microbiome-mediated therapeutics.

The Current State of Peptide Drug Discovery: Back to the Future?

Over the last decade, peptide drug discovery has experienced a revival of interest and scientific momentum, as the pharmaceutical industry has come to appreciate the role that peptide therapeutics can play in addressing unmet medical needs, and how this class of compounds can be an excellent complement or even preferable alternative to small molecule and biological therapeutics. In this perspective we give a concise description of the recent progress in peptide drug discovery in a holistic manner, highlight...

In Vitro Evaluation of the Ophthalmic Toxicity Profile of Chlorhexidine and Propamidine Isethionate Eye Drops.

Acanthamoeba keratitis causes frequent epithelial lesions that fully expose the corneal stroma. The aim of this study was to determine the toxic profile of chlorhexidine and propamidine eye drops.

An antidote approach to reduce risk and broaden utility of antibody based therapeutics.

Antibody therapeutics offer safe and effective treatment options for a broad range of diseases. One of the greatest benefits of antibody therapeutics is their extraordinarily long serum half-life, allowing infrequent dosing with long-lasting effects. One characteristic of antibodies that drives long half-life is the ability to interact with the recycling receptor, FcRn, in a pH-dependent manner. The benefit of long half-life, however, carries with it liabilities. While the positive effects of antibody thera...

In Silico Ocular Pharmacokinetic Modeling: Delivery of Topical FK962 to Retina.

To establish the in silico ocular pharmacokinetic modeling for eye drops, and to simulate the dose regimen for FK962 in human choroid/retinal diseases.

A Controlled, Randomized Double-Blind Study to Evaluate the Safety and Efficacy of Chitosan-N-Acetylcysteine for the Treatment of Dry Eye Syndrome.

This study was designed to evaluate the effect of chitosan-N-acetylcysteine (C-NAC) eye drops on tear film thickness (TFT) in patients with dry eye syndrome (DES).

Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization.

To determine the frequency and economic impact of changing initial glaucoma therapy for patients with newly diagnosed open-angle glaucoma (OAG) or ocular hypertension (OHT).

Intraarticular Injection of a Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Trial.

To evaluate the efficacy and safety of an intraarticular injection of Cingal (Anika Therapeutics, Inc., Bedford, MA) compared with Monovisc (Anika Therapeutics, Inc., Bedford, MA) or saline for the treatment of knee osteoarthritis.

Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma.

Rho-associated protein kinase (ROCK) inhibitors lower intraocular pressure (IOP) by increasing aqueous outflow through the trabecular meshwork (TM). The preclinical characterization of netarsudil, a new ROCK/norepinephrine transporter (NET) inhibitor currently in clinical development, is presented herein.

Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics.

The use of lipid formulations has greatly improved the ability to effectively deliver oligonucleotides and has been instrumental in the rapid expansion of therapeutic development programs using oligonucleotide drugs. However, the development of such complex multicomponent therapeutics requires the implementation of unique, scientifically sound approaches to the nonclinical development of these drugs, based upon a hybrid of knowledge and experiences drawn from small molecule, protein, and oligonucleotide the...

Progress and challenges in the optimization of toxin peptides for development as pain therapeutics.

The number of new toxin peptide discoveries has been rapidly growing in the past few decades. Because of progress in proteomics, sequencing technologies, and high throughput bioassays, the search for new toxin peptides from venom collections and potency optimization has become manageable. However, to date, only six toxin peptide-derived therapeutics have been approved by the USFDA, with only one, ziconotide, for a pain indication. The challenge of venom-derived peptide therapeutic development remains in imp...

Neurotrophic Keratopathy: Therapeutic Approach Using a Novel Matrix Regenerating Agent.

To evaluate the efficacy and tolerance of a new matrix-regenerating agent (RGTA), Cacicol(®), a polymer that mimics heparan sulfates bound to extracellular matrix proteins, avoiding its proteolysis, to treat neurotrophic keratopathy (NK).

Consequences of Puberty on Efficacy of Intraocular Pressure-Lowering Drugs in Male Dutch-Belted Rabbits.

To investigate the changes in intraocular pressure (IOP), aqueous flow, and outflow facility, as well as efficacy of IOP-lowering drugs before and after sexual development in rabbits.


Quick Search
Advertisement